Cipla

Roche launches COVID-19 'Antibody Cocktail' in India at Rs 59,750 per dose; Cipla to market drug in country

In a joint statement, the pharma giants said that the second batch of the Antibody Cocktail (Casirivimab and Imdevimab) will be available by mid-June

Mizoram records first COVID-19 fatality as India tally nears 80 lakh; active cases below 7 lakh for sixth day

Meanwhile, the Delhi government announced that schools will remain closed till further orders, and the DGCA extended the suspension of international passenger flights till 30 November

Cipla confirms collaboration with CSIR, IICT, ICMR to develop COVID-19 treatment

The Mumbai-based firm is also ramping up manufacturing of drugs required to treat COVID-19, like Lopinavir-Ritonavir and Hydroxychloroquine

Cipla's remdevisir to cost Rs 4,000 per 100 mg vial in India; pricing among lowest globally: Report

Cipla India business chief executive officer Nikhil Chopra said that the company was launching Cipremi commercially on Wednesday and aims to supply over 80,000 vials within the first month, but did not give details on pricing.

Mylan's remdesivir to cost Rs 4,800 per 100 mg vial in India, 80% cheaper than price tag in wealthy nations

Gilead priced remdesivir at $2,340 per patient for rich nations and agreed to send nearly all of its supply of the drug to the United States over the next three months

Sensex drops 260 points, Nifty settles below 9,050-mark at close of trading session; banking, financial stocks drag

Sensex tumbled 260 points on Friday, dragged by losses in banking and financial stocks as RBI's rate cut and other measures to prop up the economy failed to meet market expectations.

Cipla submits application with USFDA for generic version of asthma drug

Drug major Cipla on Monday said it has submitted an application with the US health regulator for a generic version of GSK's Advair Diskus, which is used in the treatment of asthma and other respiratory disorders

Sensex plunges over 800 points, Nifty slumps 227 points in early trade as economic package fails to impress

After hitting a low of 30,265.67, the Sensex was trading 731.91 points or 2.35 percent lower at 30,365.82. Similarly, NSE Nifty slumped 226.90 points, or 2.48 percent, to 8,909.95.

Cipla inks licensing pact with Gilead Sciences for potential COVID-19 treatment drug remdesivir

Homegrown pharma major Cipla Ltd on Wednesday said it has signed a non-exclusive licensing agreement with Gilead Sciences Inc for manufacturing and distribution of investigational drug remdesivir, a potential therapy for COVID-19

Hetero inks licensing agreement with Gilead for manufacturing, distribution of remdesivir

Domestic pharma major Hetero on Wednesday said it has entered into a licensing agreement with Gilead Sciences Inc for manufacturing and distribution of remdesivir, a potential therapy for COVID-19